Kellie Machlus, Ph.D.
Assistant Professor of Medicine, Harvard Medical School
Kellie is a principal investigator in the Vascular Biology Program at Boston Children’s Hospital. She is an expert in megakaryocyte- and platelet-derived extracellular vesicles and their role in megakaryocyte differentiation and inflammation.
George Vassiliou, Ph.D.
Professor of Haemat. Medicine, University of Cambridge
George is a Senior Fellow and Honorary Consultant Hematologist at Cambridge University Hospitals and heads the Haematological Cancer Genetics Group at the Sanger Institute. His research focuses on clonal hematopoiesis and the pathogenesis of blood cancers.
Lindsey George, M.D.
Director of Clinical Gene Therapy, Children’s Hospital of Philadelphia
Lindsey is an attending Physician in the Division of Hematology at Children’s Hospital of Philadelphia. She has led early phase clinical trials in AAV-mediated gene transfer for hemophilia with a focus on hemostasis and thrombosis disorders.
Eric Crombez, M.D.
Chief Medical Officer, Ultragenyx Gene Therapy
Eric is the FDA Alternate Industry Representative on the Cellular, Tissue and Gene Therapies Advisory Committee since Jan 2020. Prior to Ultragenyx, he served as CMO at Dimension Therapeutics.
Jon Rowley, Ph.D.
Founder & Chief Product Officer, Rooster Bio
Jon manages process and product development programs at Rooster Bio (previously their CEO and Technology Officer). Before Rooster, he served as innovation director, cell processing technologies at Lonza. Jon specializes in technology road-mapping, cell therapy biomanufacturing, biomaterials, and tissue engineering.
Minnie Mildwoff, M.S., J.D.
Global Therapeutics Area Lead, Novartis
Minnie is a seasoned global regulatory affairs professional with broad drug development experience in a variety of therapeutic areas and modalities. Prior to Novartis, Minnie worked in regulatory leadership roles at Cadent Therapeutics, Merrimack Pharmaceuticals, and Biogen Idec.